City

Boston (1)

Buffalo (1)

Miami (1)

Shanghai (1)

Tampa (1)

Condition

Refractory Hematologic Cancer (2)

Allogeneic Stem Cell Transplantation (1)

Overall Status

Active, not recruiting (1)

Terminated (1)

Sign in for free

Phase

phase 1/phase 2 (1)

phase 2 (1)

Sponsor

Bristol-Myers Squibb (1)

Shanghai Jiao Tong University School of Medicine (1)

Collaborator

Exelixis (1)

Intervention

cdc7-inhibitor (bms-863233) (1)

clage-flubu (1)

Study Documents

Intervention Type

drug (2)

Funder Type

Industry (1)

Other (1)

Study Type

Interventional (2)

refractory hematologic cancer

Showing 1 - 2 of 2

Trials per page:

STUDY

CONDITIONS

INTERVENTIONS

LOCATIONS

LAST UPDATED

Refractory Hematologic Cancer, Allogeneic Stem Cell Transplantation Trial in Shanghai (CLAGE-FluBu)

Active, not recruiting

Refractory Hematologic Cancer
Allogeneic Stem Cell Transplantation

CLAGE-FluBu

Shanghai, China

Blood & Marrow Transplantation Center, RuiJin Hospital

Nov 23, 2021

Refractory Hematologic Cancer Trial in United States (Cdc7-inhibitor (BMS-863233))

Terminated

Refractory Hematologic Cancer

Cdc7-inhibitor (BMS-863233)

Miami, Florida
+3 more

Sep 23, 2015